Clinical Trials Browser

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT03740165 2025-10-22

KEYLYNK-001

Phase 3 Active not recruiting

1,367 enrolled 29 charts

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

429 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3 Active not recruiting

327 enrolled 21 charts 2 FDA

Gynecologic

Ovarian Neoplasms

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Phase 1 Recruiting

24 enrolled

Gynecologic

Ovarian Neoplasms

NCT03534453 2025-07-10

L-MOCA

Phase 3 Completed

229 enrolled

Gynecologic

Ovarian Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Phase 1/2 Active not recruiting

50 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04330040 2025-03-10

SOLI

Phase 4 Completed

202 enrolled 15 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT06120972 2025-02-12

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Phase 2 Withdrawn

Gynecologic

Ovarian Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Phase 2 Recruiting

220 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase 2 Completed

265 enrolled 25 charts 2 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03737643 2025-01-29

DUO-O

Phase 3 Active not recruiting

1,407 enrolled 3 FDA

Gynecologic

Ovarian Neoplasms

NCT03314740 2025-01-10

BAROCCO

Phase 2 Completed

123 enrolled 14 charts

Gynecologic

Ovarian Neoplasms

NCT04826198 2024-12-05

REVOCAN

Phase 1/2 Terminated

13 enrolled

Gynecologic

Ovarian Neoplasms

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Phase 2 Completed

40 enrolled 16 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Phase 1 Active not recruiting

36 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03378297 2024-10-30

IMPACT

Phase EARLY_PHASE1 Completed

26 enrolled

Gynecologic

Ovarian Neoplasms

NCT06650709 2024-10-23

NEOCATS

Phase 2 Not yet recruiting

40 enrolled

Gynecologic

Ovarian Neoplasms

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Phase 1 Completed

70 enrolled 13 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT03402841 2024-08-21

OPINION

Phase 3 Completed

279 enrolled 17 charts

Gynecologic

Ovarian Neoplasms

NCT04377087 2024-08-20

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Phase 2 Terminated

3 enrolled 9 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06065059 2024-08-13

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Phase 1/2 Terminated

7 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06377267 2024-05-09

STROBE

Phase 2 Recruiting

100 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

ROSY-O

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

OVATION-3

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

BOUQUET

PROOV

QLS5132 Combination Therapy in Advanced Solid Tumors

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

MONO-OLA1

DOVACC

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

MEDIOLA

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

SOLO-1

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

KEYLYNK-001

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

L-MOCA

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

SOLI

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

DUO-O

BAROCCO

REVOCAN

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

IMPACT

NEOCATS

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

OPINION

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

STROBE